Lo SN - Search Results

1

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Goldinger SM, et al. Among authors: lo sn. Eur J Cancer. 2022 Feb;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. Eur J Cancer. 2022. PMID: 34952480

2

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. Menzies AM, et al. Cancer. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28. Cancer. 2015. PMID: 26218930 Free article.

3

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Itchins M, Ascierto PA, Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A. Itchins M, et al. Melanoma Res. 2017 Jun;27(3):243-250. doi: 10.1097/CMR.0000000000000343. Melanoma Res. 2017. PMID: 28230715

4

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.

Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Choong ES, et al. Eur J Cancer. 2017 Apr;75:169-178. doi: 10.1016/j.ejca.2017.01.007. Epub 2017 Feb 23. Eur J Cancer. 2017. PMID: 28236768

5

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.

Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF. Haydu LE, et al. J Clin Oncol. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4. J Clin Oncol. 2017. PMID: 28375785

6

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA. Vilain RE, et al. Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16. Clin Cancer Res. 2017. PMID: 28512174

7

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Parakh S, et al. Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18. Br J Cancer. 2017. PMID: 28524161 Free PMC article.

8

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Lee JHJ, Lyle M, Menzies AM, Chan MMK, Lo S, Clements A, Carlino MS, Kefford RF, Long GV. Lee JHJ, et al. Pigment Cell Melanoma Res. 2018 May;31(3):404-410. doi: 10.1111/pcmr.12675. Epub 2017 Dec 7. Pigment Cell Melanoma Res. 2018. PMID: 29171176 Clinical Trial.

9

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, Lo S, Hong AM, Menzies AM, Long GV. Tio M, et al. Pigment Cell Melanoma Res. 2018 Jul;31(4):509-515. doi: 10.1111/pcmr.12682. Epub 2018 Jan 10. Pigment Cell Melanoma Res. 2018. PMID: 29277979 Clinical Trial.

10

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Lee JH, et al. JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332. JAMA Oncol. 2018. PMID: 29423503 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page